SALT LAKE CITY, August 5, 2025 — Leads & Copy — Myriad Genetics, Inc. (NASDAQ: MYGN) announced its second-quarter financial results for the period ended June 30, 2025, and updated its full-year financial guidance.
Second quarter 2025 revenue reached $213.1 million, a 1% increase year-over-year. Excluding headwinds of $9.5 million, revenue increased 5% year-over-year. Hereditary cancer testing revenue and volume in Oncology grew 9% and 10% year-over-year, respectively. Gross margin of 71.2% increased over 160 basis points year-over-year. GAAP net loss was $330.5 million, or $(3.57) per share, reflecting non-cash impairment charges of $316.7 million. Adjusted EPS was $0.05. On July 31, 2025, Myriad entered into a new $200 million credit facility.
The company has raised its 2025 revenue guidance to $818 – $828 million, from $807 – $823 million, and reiterated adjusted EPS range of $(0.02) – $0.02, reflecting second quarter results, interest expense under the new credit facility, and the current business outlook.
Myriad Genetics President and CEO Sam Raha said the company delivered solid second-quarter results driven by continued strength in hereditary cancer testing in oncology. He added that Myriad has made significant progress on updating its strategy and intends to accelerate growth by focusing future investments on more comprehensively serving screening and diagnostic applications across the Cancer Care Continuum while being disciplined on driving targeted profitable growth from other businesses.
Myriad Genetics is a molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all.
Investor Contact:
Matt Scalo
(801) 584-3532
matt.scalo@myriad.com
Media Contact:
Kate Schraml
(224) 875-4493
PR@myriad.com
Source: Myriad Genetics, Inc.
